SCHEMBL1086313

SCHEMBL1086313

N#Cc1ccccc1CN1CC2(CCN(C(=O)O)CC2)OC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
BRD4 O60885 1/20 0.39
OPRM1 P35372 2/20 0.38
OPRL1 P41146 1/20 0.38
DPP4 P27487 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
TACR2 P21452 1/20 0.37
TACR1 P25103 1/20 0.37
COMT P21964 1/20 0.36
RIPK1 Q13546 1/20 0.35
FEN1 P39748 1/20 0.35
CCR5 P51681 1/20 0.35
GALR3 O60755 1/20 0.35
ALDH1A1 P00352 1/20 0.35
RAB9A P51151 1/20 0.35
NOX4 Q9NPH5 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1085983 0.85 SIRT2 (0.39) SIRT2SIRT1BRD4OPRM1OPRL1
SCHEMBL1086613 0.85 HTT (0.40) SIRT2SIRT1BRD4OPRM1OPRL1
SCHEMBL1086595 0.84 SIRT2 (0.41) SIRT2SIRT1BRD4OPRM1OPRL1
SCHEMBL1086453 0.84 L3MBTL1 (0.44) SIRT2SIRT1HCRTR1HCRTR2ALDH1A1
SCHEMBL1085767 0.83 RIPK1 (0.52) SIRT2SIRT1OPRM1TACR2TACR1
SCHEMBL1086243 0.82 GRM2 (0.39) OPRM1TACR2TACR1RIPK1SIGMAR1
SCHEMBL1086826 0.82 ALDH1A1 (0.49) SIRT2SIRT1ALDH1A1RAB9ATSHR
SCHEMBL1086541 0.82 RIPK1 (0.41) SIRT2SIRT1DPP4TACR2TACR1
SCHEMBL1085855 0.81 RIPK1 (0.49) OPRM1TACR2TACR1RIPK1ALDH1A1
SCHEMBL1087072 0.81 POLB (0.39) SIRT2SIRT1OPRM1OPRL1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC SIRT2 205/4885SIRT1 92/4885BRD4 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.